2022 Agenda

  • Day One includes the following topics:

    • Discovery/Preclinical Science
    • Advancements in IO Imaging
    • Clinical Operations
    • Translational Science & Emerging Biomarkers Part 1
    • Cancer Immunotherapy Debate
  • 7:30 am

  • Registration

  • 8:15 am

  • IO360° Opening Remarks

    Axel Hoos, MD, PhD
    CEO, Scorpion Therapeutics

    James Gulley, MD, PhD
    Chief, Genitourinary Malignancies Branch, Director, Medical Oncology Service, Center for Cancer Research, National Cancer Institute, NIH

  • 8:25 am



    Nobel Laureate Keynote: Mechanisms of Immune Evasion Mediated by Hypoxia-Inducible Factors 

    In this session Dr Semeza will talk about how his work is impacting cancer immunotherapy. Dr Semenza’s groundbreaking discovery of hypoxia-inducible factors paves the way for the development of drugs that could kill cancer cells by cutting off the oxygen supply tumors need to grow and improve the response to immunotherapies. Key areas addressed include:

    • Regions of intratumoral hypoxia are a common feature of advanced cancers
    • Hypoxia-inducible factors increase the expression of multiple proteins that mediate immune evasion
    • HIF inhibitors stimulate anti-tumor immunity and improve the response to immune checkpoint blockade

    Gregg Semenza, MD, PhD
    Director, Vascular Program, Institute for Cell Engineering  and Professor of Genetic Medicine
    Johns Hopkins University School of Medicine

    About Dr Semenza:

    Dr Semenza’s lab discovered hypoxia-inducible factor 1 (HIF-1), a transcription factor that controls the expression of thousands of genes in response to changes in oxygen availability, for which he received the 2019 Nobel Prize in Physiology or Medicine. His current research interests include investigating the molecular mechanisms of oxygen homeostasis and the role of HIF-1 in cancer progression. Dr Semenza is co-founder of HIF Therapeutics Inc., which is focused on the development of HIF inhibitors for the treatment of cancer and blinding eye diseases.


  • 8:50 am



    ZEITGEIST TALK: Cancer Immunity Life Cycle

    A Decade After Checkpoints- What Do We Know, What Do We Need to Know and Getting There Faster

    Dan Chen, MD, PhD
    Physician Scientist, Cancer Immunotherapy and Board of Directors
    Society for Immunotherapy of Cancer (SITC)




  • 9:10 am

  • GARP as a New IO Target

    Zihai Li, MD, PhD
    Founding Director, OSUCCC – James Pelotonia Institute for Immuno-Oncology; Professor of Internal Medicine, Klotz Chair in Cancer Research, Ohio State University


  • 9:30 am




    • Grab-n-Go Breakfast
    • Networking
    • Meet the Exhibitors


  • 10:15 am




    Advancing Immunotherapy Efficacy by Understanding Resistance

    Thomas Gajewski, MD, PhD
    AbbVie Foundation Professor of Pathology
    University of Chicago



  • 10:35 am

  • How to Develop a Diverse Pipeline in a Post Checkpoint Inhibitor World

    Lilli Petruzzelli, MD, PhD
    SVP, Early Clinical Development, Genentech

  • 10:55 am

  • Dissecting the CD226 Axis: Opportunities for TIGIT, CD96, and PVRIG in Cancer Immunotherapy

    • Thorough CyTOF-based phenotypic evaluation of the CD226 axis in human tumors
    • Characteristics of TIGIT, PVRIG, and CD96 – cell types and predicted functions.
    • Implications of Fc biology for CD226 axis therapeutics.

    Jeremy Waight, PhD
    Scientific Director, GSK

  • 11:15 am

  • Reserved Case Study

  • 11:30 am

  • The Quest for the Perfect IO Bispecific: Can We Solve the Question 1+1=?

    • Review the successes and lessons learned in bispecific research & development
    • Evaluate where the focus is today and how bispecifics fit in the landscape
    • Discuss opportunities to revolutionize the IO landscape and develop transformative medicines

    Zhen Su, MD, MBA
    CEO, Marengo Therapeutics

  • 11:50 am

  • Reserved Case Study



  • 12:05 pm



    Lunch & Partnering Meetings Begin

    • Grab-n-Go Lunch
    • Partnering Tables
    • Networking
    • Meet the Exhibitors
    • “Charge-up” at the IO360° Charging Stations


  • Two Track Choices

    • TRACK A

      Advancements in IO Imaging 

    • 1:00 pm – 1:20 pm 

      Molecularly Targeted Imaging Approaches To Give More Insight Into the Science and Mechanisms

      Charlie Glaus, PhD

      Director, Translational Research & Early Clinical Development, Takeda


    • 1:20 pm – 1:35 pm 

      Clario Case Study


    • 1:35 pm – 1:55 pm 

      Developing CD8 Imaging for Clinical Trials

      • The value of CD8 PET for early phase oncology clinical trials
      • Initial clinical experience using 89Zr-anti-CD8
      • Progress in developing an 18F nanobody tracer for CD8

      Alex de Crespigny, PhD

      Head of Clinical Imaging Group, Genentech

      Simon Williams, PhD

      Principal Scientist, Genentech



    • 1:55 pm – 2:10 pm 

      Imaging Endpoints Case Study

      Ron Korn, MD, PhD

      Founder, Chairman and Chief Medical Officer, Imaging Endpoints

    • 2:10 pm – 2:40 pm 

      Panel: Targeted Radiotherapy and the Impact on IO

      • What is the impact of targeted radiotherapy on the immune system?
      • What are the implications for combination IO?
      • Current approaches and future direction

      Moderated by:

      Michael Groaning, PhD
      Global Medical Affairs Lead, Genitourinary, Amgen


      Jeff Legos, PhD, MBA
      EVP, Global Head of Oncology & Hematology Development, Novartis



    • 2:40 pm – 3:20 pm 

      Panel: Advances in Using Novel Biology Driven Imaging Techniques to Help Inform Drug Development
      Over the last four decades, CT, MRI, and even X ray have been used to really measure the size of tumors. This has been an extreme oversimplification and ignorant of the tumor biology. This panel addresses beyond digital caliper, what else has been accomplished once we recognized the limitation of it? Key topics include:

      • Historical context on where we have been and what was able to be accomplished previously
      • What we have been doing with radiomics to generate more biology that is hidden within the images
      • Use of molecular techniques, such as FDG PET in solid tumors and molecular PET probes (CD8, etc)
      • Other metabolic approaches and what is next

      Moderated by:

      Antonio “Tito” Fojo, MD, PhD

      Professor of Medicine, Columbia University


      Michael Groaning, PhD
      Global Medical Affairs Lead, Genitourinary, Amgen

      David Leung, MD, PhD
      Senior Director, Imaging, BMS

      Ron Korn, MD, PhD

      Founder, Chairman and Chief Medical Officer, Imaging Endpoints

    • 3:20 pm 

      End of Track

    • TRACK B

      Clinical Operations

    • 1:00 pm – 1:45 pm

      Diversity and Inclusion Across All Operation Functions

      This panel will address diversity and inclusion issues that influence the IO space and ways to overcome them.

      Chétna Rao, PhD
      Head of Site Strategy and Operations, BMS

      Robert Vonderheide, MD, DPhil
      Director, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania

      Karen Peterson
      Cancer Veteran and Founder, Karen’s Club

    • 1:45 pm – 2:35 pm 

      Two Collaboration Case Studies: How You Adapted Your Trial Operations to Continue to Move Forward During the Pandemic and What Will Stick

      • What did you do to engage with your investigator when enrollment may not have been where it needed to be?
      • What were the creative things that the teams did? collectively?
      • Was the room an RS a remote site monitoring strategy in place beforehand? If not, what were the considerations to move to that strategy mid-flight? What was the final outcome?
      • How did you lock your database with assurance that the data were of registration worthy quality?
      • And then were you inspected? And if so, were there learnings from the inspection that have caused you to consider your approach moving forward?





    • 2:35 pm – 3:20 pm 

      Navigating the Lingering Impact of COVID-19 on IO Clinical Trial Operations and Actions to Address Them

      This panel focuses on how to address the ongoing operational challenges along with dealing with lingering trial disruptions as a result of COVID-19. Key topics addressed:

      • Patient recruitment and retention challenges
      • Weekly infusions, risking themselves by going to clinic weekly
      • Remote monitoring challenges and ensuring patients are being dosed appropriately
      • How to clear data backlog (or remnants of) in a pandemic situation
      • How to mitigate site burden
      • How to prepare sites to be audit ready with the added challenges imposed by COVID
      • How to establish premier site relationships
      • Decentralization of Procedures and How that is playing out for IO trials

      Shree Patel, PhD
      SVP, Clinical Operations , Achilles Therapeutics

      Julie Martin, MBA
      CEO , Scimega

      Andrea Perrone, MD
      AVP, Global Clinical Operations, Head of Clinical Scientists and Study Management, Oncology, Merck















    • 3:20 pm

      End of Track

  • 3:20 pm



    Afternoon Break in the Exhibit Cafe

    • Refreshments including chocolate samples & chocolate coins
    • Partnering Tables
    • Meet the Exhibitors
    • Networking
    • “Charge-up” at the IO360° Charging Stations




  • 4:00 pm

  • New Immuno-metabolic Impact on Cancer Vaccination Data

    Lisa Butterfield, PhD
    VP, Research and Development, Parker Institute for Cancer Immunotherapy

  • 4:20 pm

  • Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform: ImmunoID NeXT™

    Angela Qu
    Erin Newburn, PhD
    Associate Director, Field Applications Scientist, Personalis, Inc

  • 4:35 pm

  • Enhancing the Interferon Pathway to Attack Cancer – Not a One-Size-Fits-All Approach

    • Why is enhancing the interferon pathway an attractive approach for treating cancer?
    • What are the novel therapeutic approaches being investigated to harness the innate immune system to enhance the interferon pathway to treat cancer?
    • What are the translational approaches being applied to better study therapeutics that activate the interferon pathway against hematologic and solid tumors and identify the patients who may respond better to these therapeutics?

    Scott Norberg
    Christine Ward, PhD
    Head, Oncology Precision and Translational Medicine, Takeda Pharmaceuticals

  • 4:55 pm

  • Opportunities to Inform Early Development Using PET Methods

    This talk includes a scientific point of view that demonstrates insight into mechanism, insight into translational work using PET. Case examples will be included.

  • 5:10 pm

  • Update on CD40 Cancer Immunotherapy

    Robert Vonderheide, MD, DPhil
    Director, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania


  • 5:30 pm


    IO360° Cancer Immunotherapy Debate

    NK-CARs vs T cell-CARs 

    When it comes to cell therapy, are natural T-cells more superior than NK cells? How much will memory and the ability to have the adaptive response really play when using NK cells as a cell therapy vs CAR-T cells?

    Kristen Hege, MD, SVP, Early Clinical Development, Hematology/Oncology and Cell Therapy, BMS


    Bob Valamehr, PhD, MBA, Chief R&D Officer,Fate Therapeutics

    Debate Moderator:

    Daniel Chen new
    Dan Chen, MD, PhD, Physician Scientist, Cancer Immunotherapy and Board of Directors, Society for Immunotherapy of Cancer (SITC)


  • 6:00 pm

  • End of Day One

2022 Agenda

  • Day Two includes the following topics:

    • Business Developments
    • IO Novel Technologies
    • Translational Science & Emerging Biomarkers Part 2
    • Cell & Gene Therapy Day
  • 7:30 am

  • Registration, Exhibits & Partnering Meetings

  • 8:15 am

  • IO360° Day Two Welcome

  • 8:25 am



    Innovative CRISPR-based Editing to Create Off-the-shelf Immune Cell Therapies for Hematologic and Solid Tumors

    In this talk, Dr Rachel Haurwitz, CEO, Caribou Biosciences, addresses the big picture view of where the cell therapy field is going and how innovative CRISPR-based editing will help with the treatment of hematologic and solid tumors. Key topics:

    • Approach that requires highly specific and efficient multiplex genome editing
    • What are some of the potential stumbling blocks?
    • What are the tools for solving those challenges?
    • Tackling solid tumors as the next frontier for cell therapies

    Rachel Haurwitz, PhD
    President & CEO, Caribou Biosciences


  • 8:50 am



    How COVID-19 Success Impacted BioNTech’s Business Development Strategy

    Zach Taylor, MBA
    VP, Corporate Development and Strategy, BioNTech US


    Mark Simon, MBA
    Managing Director, Torreya Partners



  • 9:15 am



    What’s Next on the IO Radar? Top 10 Recommendations from Citi’s Expert Analyst, Dr Andrew Baum

    Andrew Baum, MD
    Managing Director, Equity Research, Citi

  • 9:35 am

  • Morning Networking Cafe, Exhibits & Partnering Meetings

    • Grab-n-Go Breakfast
    • Partnering Tables
    • Networking
    • Meet the Exhibitors
    • IO360° Swag Tables


  • 10:15 am

  • Choice Between Business Developments, Translational Science & Emerging Biomarkers and Cell & Gene Therapy Day

    • TRACK A


    • 10:15 am – 10:35 am 



      Regeneron’s Approach to Strategic Collaborations, Licensing and Business Development  

      Nouhad Husseini, MBA
      SVP, Business Development and Corporate Strategy, Regeneron Pharmaceuticals


      Mark Simon, MBA
      Managing Director, Torreya Partners


    • 10:35 am – 11:15 am

      Investment Trends in IO
      This panel will delve into what is driving investment in IO 2.0?

      Moderated by:

      Axel Hoos, MD, PhD
      CEO, Scorpion Therapeutics


      Jonathan Fassberg
      Vice Chairman of Healthcare Investment Banking, Oppenheimer

      Mark Simon, MBA 
      Co-founder & Advisor, Torreya Partners

      Otello Stampacchia, PhD
      Founder, Omega Funds

    • TRACK B


    • 10:15 am – 10:35 am

      Recent Regulatory Developments for CAR-T Cells 

      Dr Peter Marks, FDA provides an update on the draft guidance on sameness and other regulatory developments for CAR-T cells.

      Peter Marks, MD, PhD
      Director, Center for Biologics Evaluation and Research (CBER), FDA




    • 10:35 am – 10:55 am

      Current Landscape of Cell & Gene Therapy   

      • Where have we come over the past 5 years
      • What are the approvals and approval activity over the past year?
      • What are the challenges and issues?
      • What have we learned?
      • What are the real important technologies that are being developed that might help transform the cell and gene therapy space?
      • What are the key things we need to think about moving forward?

      Michael Kalos, PhD
      Managing Director, Next Pillar Consulting

    • 10:55 am – 11:35 am

      Investment and Collaboration Strategies in Cell and Gene Therapy  

      2020/2021 was a strong year for biotech investments in the cell and gene therapy sector. Well over $20 billion of funding flowed in stemming from venture capital financing, IPO investments and upfront payments in partnerships and collaboration deals with evidence of clinical progress but no clinical data from programs. This panel will address:

      • What are the risks and implications of investing in cell/gene therapy companies who have no clinical data from programs available?
      • Venture company perspectives on what they are investing in and why?
      • What science needs to be seen in order to invest in either a startup or IPO?
      • What are investors/pharma partners looking for and how does that inform what people should be doing?
      • How do we think about partnerships between organizations?

      Moderated by:

      Michael Polansky
      CEO, Parker Group


      Mark Bonyhadi, PhD
      Senior Advisor, Qiming Venture Partners

      Elaine Cheung
      SVP, Corporate Strategy & Business Development, Lyell Immunopharma

      Lei Meng, MBA
      Senior Therapeutics Analyst, Avidity Partners


    • 11:15 am – 12:05 pm

      This session showcases companies that have technologies and solutions that will help stakeholders in the IO field advance developments that provide treatment for cancer patients.

    • 12:05 pm – 12:45 pm

      Assessing the Opportunities for IO 2.0

      Moderated by:

      Jeff Bockman, PhD
      EVP & Head, Oncology Practice, Cello Health


      Jake Becraft, PhD
      CEO & Co-founder, Strand Therapeutics

      Sharon Benzeno, PhD
      Chief Business Development Officer, Adaptive Biotechnologies

      Matt Call, MBA
      Chief Operating Officer, iTeos Therapeutics

      Ariella Evenzahav, PhD
      Executive Director, Global Development Strategy, BeiGene

      Prakash Raman, PhD
      Senior Partner, Chief Business Development Officer, Flagship Pioneering





    • 11:35 am – 12:25 pm

      This session features companies that have manufacturing engineering innovations that will help accelerate the process and development of cancer cell-based immunotherapies.


    • 12:25 pm – 12:45 pm

      Progress on ATA2271, An Industry Leading Program to Address Challenges of Solid Tumors with CAR-T

      ATA2271 is the first and only CAR-T in the clinic with a PD1 Dominant Negative Receptor and a new co-stimulatory domain called 1XX to allow for more functional persistence and an original way to address the challenges of solid tumors for cell therapies. This talk will address:

      • How to avoid T Cell exhaustion for increased functional persistence of CART in solid tumors
      • PD1 DNR to address TME immunosuppression
      • Clinical experience with mesothelin-1XX-PD1 DNR  CART in advanced mesothelioma
      • Benefits of an allogeneic approach for solid tumors with mesothelin CART EBV T Cells
      Jakob Dupont
      Jakob Dupont, MD
      Global Head of Research & Development and EVP, Atara Biotherapeutics


  • 12:45 pm


    Lunch & Partnering Meetings

    • Grab-n-Go Lunch
    • Partnering Tables
    • Networking
    • Meet the Exhibitors
    • “Charge-up” at the IO360 ̊ Charging Stations




    • 1:45 pm – 2:05 pm

      Landscape Talk: What is Coming out of Biomarker Signals from Checkpoint Inhibitors?

      This talk will address:

      • State of most widely used predictors of response biomarkers: PD-L1, TMB and their use in real world (implications for space for IO doublet usage in the real world setting)
      • Signals associated with mechanisms of resistance both tumor intrinsic and systemic- what has held up, what have combination studies to address resistance told us
      • Biomarkers being employed for early disease intervention – should we be going the all comer route in early disease or focus on addressing unmet need post surgery

      Priti Hedge, PhD
      Chief Scientific Officer, Foundation Medicine

    • 2:05 pm – 2:20 pm

      Parexel Case Study

    • 2:20 pm – 2:35 pm

      Advances in Immunotherapy Clinical Trial Design with ctDNA MRD

      • Applications of ctDNA MRD in clinical trials to identify patients most likely to benefit from additional treatment and to predict therapy efficacy
      • Latest clinical data using ctDNA across patient stratification, enrichment, and monitoring in studies involving immunotherapies
      • Outlook for ctDNA as a surrogate endpoint and in accelerating clinical development

      John Simmons, PhD
      Global Vice President, Biopharma Business Development, Natera

    • 2:35 pm – 2:55 pm

      Astellas Pharma’s IO Cell Therapy and Translational Science Strategies

      Peter Sandor, MD, MBA
      SVP, Oncology, Astellas Pharma US

    • 2:55 pm – 3:10 pm

      Utility of multiplexed Immunofluorescence to Spatially Resolve Immune Tumor Heterogeneity

      Multiplex immunofluorescence (mIF) on tissue biopsies provides critical insight into the tumor-immune microenvironment (TiME), affording a comprehensive study of cellular composition, cellular functions, and cell-cell interactions. High-level multiplexing, whole slide imaging, and spatial quantitative image analysis are all must-have requirements for effective mIF solutions. In this session, Ultivue’s Dr. Keith Wharton guides research scientists and clinicians through the deployment and utility of a high throughput, high-plex staining protocol coupled to advanced quantitative image analysis, thus enabling a detailed assessment of the immune cell types and interactions of the TiME associated with specific cancer types and allowing researchers to reveal the true biology of each patient’s tissue sample. Key topics:
      • Introduction to InSituPlex® DNA-barcoding and antibody staining technology for multiplex fluorescence applications
      • How to make use of multi-parameter data within the TME – spatial mapping, dynamic range of expression, and co-localization of markers on individual cells
      • Introduction to new UltiStackerTM software, which allows a detailed spatial characterization of specific cell phenotypes defined by co- or lack of expression that may help in predicting clinical responses and mechanisms of resistance to therapy.

      Keith Wharton MD, PhD
      VP Medical Director, Ultivue


    • 1:45 pm – 2:05 pm



      Advancements in CART for the Treatment of Glioblastoma

      Christine Brown, PhD
      Deputy Director, T Cell Therapeutics Research Laboratory, Beckman Research Institute, City of Hope


    • 2:05 pm – 2:25 pm

      Lessons Learned from CART-PSMA-TGFβRDN and Next Steps

      Joseph Fraietta, PhD
      Assistant Professor of Microbiology, Center for Cellular Immunotherapies, University of Pennsylvania

    • 2:25 pm – 2:45 pm

      BMS’ Journey to Approval for 2 CARTs, Lessons Learned and Future Outlook

      John Lo
      SVP- WW Hematology, Bristol-Myers Squibb

    • 2:45 pm – 3:05 pm

      Fate Therapeutics on ISPC and NK Platform Clinical Data and Approvals

      Bob Valamehr, PhD, MBA
      Chief R&D Officer, Fate Therapeutics

  • 3:10 pm

  • Afternoon Networking Break & Partnering Meetings

    • Ice Cream
    • Partnering Tables
    • Meet the Exhibitors
    • Networking
    • “Charge-up” at the IO360° Charging Stations


    • 3:50 pm – 4:10 pm

      Primary Resistance vs Secondary Resistance and the Implications for Combination Treatments

      Ryan Sullivan, MD
      Assistant Professor of Medicine / Assistant Professor in Hematology/Oncology, Harvard Medical School / Massachusetts General Hospital





    • 4:10 pm – 4:25 pm

      10X Genomics Case Study




    • 4:25 pm – 4:45 pm

      The Resurgence of Cytokines for Cancer Immunotherapy: Lessons Learned and New Opportunities

      This talk will span basic/translational as well as clinical aspects of the use of cytokines and future opportunities.

      Jon Wigginton, MD
      Chairman, Scientific Advisory Board & Senior Advisor, Cullinan Oncology

    • 4:45 pm – 5:00 pm

      Reserved Case Study

    • 5:00 pm – 5:20 pm

      Shedding New Light on the Power of the Adenosine Pathway

      • Recent clinical data validating the potential of adenosine targets suggests that this pathway is a promising source of innovation in the treatment of various cancers.
      • A widening body of evidence supports the biological rationale for targeting CD39 and CD73 on the adenosine pathway to stimulate anti-tumor immune responses.
      • Current studies demonstrate potential to employ adenosine modulation to treat multiple indications, including pancreatic and prostate cancer.

      Rob Ross, MD
      CEO, Surface Oncology 

    • 5:20 pm – 6:00 pm

      Incorporating Advances in Biomarker Development to Inform Clinical Decisions and Lessons Learned

      • When evaluating combination therapies, what should we be doing from a pharmacodynamic perspective to gain confidence in whether the combination activity is greater than expected from single-agent treatment? What is the science telling us?
      • How do we develop biomarkers in phase one and phase two studies that will impact what’s ultimately approved as a companion diagnostic?
      • What biomarkers can we measure in early oncology studies to give us more confidence in our subsequent steps in clinical development?
      • How can we apply lessons learned from PD one and PDL1 development to other immuno-oncology agents, for example developing diagnostics for situations in which the target or target biology are similar? How can we unify efforts across industry?
      • ctDNA as a drug development tool:
        • What are the advances in using circulating tumor DNA as a surrogate endpoint or as an early signal for clinical efficacy
        • How do these dynamics of ctDNA complement what we use today as standard criteria for responses
        • What are the potential regulatory and exploratory applications of on-treatment ctDNA?

      Lynn Navale
      VP, Biometrics, Allogene Therapeutics

      Angel Rodriguez, MD
      Oncology Medical Director, Natera

      Francesca Zolezzi, PhD
      Director Integrated Biomarker Solutions, Translational Sciences, Early Phase Operations, Syneos Health


    • 3:50 pm – 4:10 pm

      Integration of Cell Therapy with Single Cell Multi-omics

      This session addresses t-cell exhaustion with a focus on integration of cell therapy with single cell multi-omics and how it helps us understand at the single cell level, what is going on in T cells to understand the dysfunctional state.

      John Wherry, PhD
      Director, Institute for Immunology, Chair, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania School of Medicine

    • 4:10 pm – 4:30 pm

      BCMA Targeted Treatment for Multiple Myeloma

      Barbra Sasu, PhD
      Chief Scientific Officer, Allogene Therapeutics

    • 4:30 pm – 4:45 pm

      Integration of Single Cell Genomics to Improve Cell Therapy Development

      Danny Wells, PhD
      SVP, Strategic Research & Scientific Co-founder, ImmunAI



    • 4:45 pm – 5:00 pm

      Adaptive Biotechnologies Case Study

      Sharon Benzeno, PhD
      Chief Business Development Officer, Adaptive Biotechnologies

    • 5:00 pm – 5:15 pm

      Reserved Case Study

    • 5:15 pm – 6:00 pm

      Synthetic Biology as a Way to Make Better Cell Therapies

      • Current approaches to synthetic biology
      • How do you actually apply these technologies effectively?
      • What are the questions that can be addressed?
      • What are the approaches to address those?
      • What limitations can we imagine can come out of them that we have to think about further?

      Moderated by:

      Michael Kalos, PhD
      Managing Director, Next Pillar Consulting


      Mark Kotter, MD, PhD
      Founder/CEO, bit.bio

      Nick Haining, MD 
      CSO, Arsenal Bio

      Celeste Richardson, PhD
      SVP, Research, Catamaran Bio


  • 6:00 pm

  • 7th Annual Networking Reception & Partnering Meetings

2022 Agenda

  • Day Three includes the following topics:

    • NeoAdjuvant/Adjuvant Updates
    • Bispecifics
    • IO Clinical Developments


  • 7:45 am

  • Registration, Exhibits & Partnering Meetings

  • 8:15 am

  • IO360° Day Three Welcome

  • 8:30 am


    IO Combination Trial Experience: Lessons from a Patient

    We are honored to welcome Karen Peterson, patient #1 in a metastatic triple-negative breast cancer immunotherapy combination trial at NYU Langone Cancer Center, who in this fireside chat provides personal insights on her trial journey, which has led her to her advocacy work to raise clinical trial education and awareness in underrepresented communities.

    Karen Peterson
    Cancer Veteran and Founder, Karen’s Club

  • 8:50 am


    Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Primary Resistance


    Suzanne Topalian, MD
    Associate Director / Professor of Surgery
    Bloomberg~Kimmel Institute for Cancer Immunotherapy / Johns Hopkins University

  • 9:15 am


    Morning IO360° Networking Cafe, Exhibits & Partnering Meetings

    • Grab-n-Go Breakfast
    • Partnering Tables
    • Networking
    • Meet the Exhibitors
    • IO360° Swag Tables



  • 10:00 am

  • ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma

    Sanjeev Mariathasan, PhD
    Senior Principal Scientist, Oncology Biomarker Development, Genentech

  • 10:20 am

  • Progress Report on AstraZeneca’s Adjuvant Pacific Trial

    Raluca Verona
    Cristian Massacesi, MD
    SVP, Head of Late Development Oncology R&D, AstraZeneca

  • 10:40 am

  • Merck NeoAdjuvant and Adjuvant Updates on Breast Cancer and Adjuvant Updates for Renal Cancer

    Vassiliki (Valia) Karantza, MD, PhD
    Associate Vice President – Global Clinical Development, Women’s Cancers – Sub-Section Head for Breast Cancer, Merck

  • 11:00 am

  • Progress on NeoAdjuvant Combination NEOSTAR Study: Nivolumab + Ipilimumab in NSCLC

    Tina Cascone, MD, PhD
    Assistant Professor, Thoracic and Head and Neck Cancer, MD Anderson Cancer Center


  • 11:20 am

  • Recent Clinical Data on PSMA BiTE® Molecule, AMG 160

    Margit (Maggie) Janát-Amsbury, MD, PhD
    Medical Director Oncology Early Clinical Development, Amgen

  • 11:40 am

  • Preclinical Update on Regeneron’s CD28

    Bei Wang, MD, PhD
    Associate Director, Regeneron

  • 12:00 pm

  • Novel Approaches to Expand the Therapeutic Index of T cell Engagers

    T cell engagers have shown remarkable efficacy in the clinic, but their clinical utility can be limited by toxicities. The nature of the observed toxicities depends on properties of the therapeutic modality as well as the therapeutic target and indication. This talk will discuss the utility of constitutively active versus spatially or temporally controlled conditionally active T cell engagers.

    Holger Wesche, PhD
    CSO, Harpoon Therapeutics

  • 12:20 pm

  • Panel: Next Generation Bispecifics

    • What are the different classes of the biospecifics that are really showing some activities?
    • What are the next generation bispecifics to be explored?
    • Bispecifics targeting multiple checkpoints – does this change the next gen of molecules?
    • What are the emerging mechanisms of response or resistance?
  • 1:00 pm


    Lunch & Partnering Meetings

    • Lunch on your own
    • Networking
    • “Charge-up” at the IO360 ̊ Charging Stations



  • 1:50 pm

  • What’s Next: Merck’s Additional Phase III Readouts Expand IO Leadership into Early Stage Cancers and Additional Tumor Types

    Roy Baynes, MD, PhD
    Global Head, Clinical Development, Merck Research Labs

  • 2:10 pm

  • LAG3 + Opdivo in Melanoma

    Jonathan Cheng, MD
    SVP and Head, Oncology Development, BMS

  • 2:30 pm

  • Reimagining Prostate Cancer with Targeted Radioligand Therapy: A VISION Study Update

    Jeff Legos, PhD, MBA
    EVP, Global Head, Oncology & Hematology Development, Novartis


  • 2:50 pm

  • DREAMM-5 study involving BCMA ADC + IO Combos

    Ira Gupta, MD, VP, Medicines Development Leader – Oncology, GSK

  • 3:10 pm

  • Overcoming Relapse After CART Therapy in Lymphoid Malignancies

    • Review the most novel mechanisms of relapse after CART19 therapy in B-cell lymphomas and leukemias
    • Discuss recent findings on strategies to overcome resistance
    • Future perspective and next generation CART platforms

    Marco Ruella, MD, Assistant Professor of Medicine / Scientific Director, Lymphoma Program, Division of Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania


  • 3:30 pm

  • Update on EOS-448, an anti-TIGIT Monoclonal Antibody,Eenabling Novel Next-Generation Immuno-oncology Combinations

    Joanne Lager, MD
    CMO, iTeos Therapeutics

  • 3:50 pm

  • End of Conference